Insulet Company Insiders
| PODD Stock | USD 288.73 2.78 0.95% |
Insulet employs about 3.9 K people. The company is managed by 30 executives with a total tenure of roughly 54 years, averaging almost 1.0 years of service per executive, having 130.0 employees per reported executive. Evaluation of Insulet's management performance can provide insight into the firm performance.
| James Hollingshead CEO CEO President |
| Eric Benjamin President Senior Vice President R&D, New Product Development and Commercialization |
Insulet's latest congressional trading
Congressional trading in companies like Insulet, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Insulet by those in governmental positions are based on the same information available to the general public.
| 2025-09-12 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
| 2025-08-13 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
| 2025-08-11 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
| 2025-07-30 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
| 2025-07-29 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
| 2024-04-18 | Senator Tina Smith | Acquired $50K to $100K | Verify | ||
| 2024-01-25 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
| 2020-04-16 | Senator Tina Smith | Acquired $250K to $500K | Verify | ||
| 2020-04-15 | Senator Tina Smith | Acquired $250K to $500K | Verify | ||
| 2018-09-19 | Senator Tina Smith | Acquired $250K to $500K | Verify | ||
| 2018-09-18 | Senator Tina Smith | Acquired $15K to $50K | Verify | ||
| 2018-06-11 | Senator Tina Smith | Acquired $100K to $250K | Verify | ||
| 2018-06-10 | Senator Tina Smith | Acquired $100K to $250K | Verify | ||
| 2018-03-06 | Senator Tina Smith | Acquired $100K to $250K | Verify | ||
| 2018-03-05 | Senator Tina Smith | Acquired $100K to $250K | Verify |
Insulet Management Team Effectiveness
The company has return on total asset (ROA) of 0.0874 % which means that it generated a profit of $0.0874 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1968 %, meaning that it created $0.1968 on every $100 dollars invested by stockholders. Insulet's management efficiency ratios could be used to measure how well Insulet manages its routine affairs as well as how well it operates its assets and liabilities.Insulet Workforce Comparison
Insulet is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 273,727. Insulet claims roughly 3,900 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Profit Margin (PM) of 0.1 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.17 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.17. Insulet Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Insulet insiders, such as employees or executives, is commonly permitted as long as it does not rely on Insulet's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Insulet insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dan Manea over six months ago Disposition of 1300 shares by Dan Manea of Insulet at 300.05 subject to Rule 16b-3 | ||
Ana Chadwick over six months ago Disposition of 1765 shares by Ana Chadwick of Insulet at 250.25 subject to Rule 16b-3 | ||
Eric Benjamin over six months ago Disposition of 12394 shares by Eric Benjamin of Insulet at 280.0 subject to Rule 16b-3 | ||
Laetitia Cousin over six months ago Disposition of tradable shares by Laetitia Cousin of Insulet at 272.27 subject to Rule 16b-3 | ||
Frederick Wayne A.i. over six months ago Disposition of 1825 shares by Frederick Wayne A.i. of Insulet at 275.0 subject to Rule 16b-3 | ||
Eric Benjamin over six months ago Disposition of 1875 shares by Eric Benjamin of Insulet at 74.5 subject to Rule 16b-3 | ||
Eric Benjamin over six months ago Disposition of 3371 shares by Eric Benjamin of Insulet at 74.5 subject to Rule 16b-3 | ||
Eric Benjamin over six months ago Disposition of 4362 shares by Eric Benjamin of Insulet at 267.6 subject to Rule 16b-3 |
Insulet Notable Stakeholders
An Insulet stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Insulet often face trade-offs trying to please all of them. Insulet's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Insulet's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| James Hollingshead | CEO President | Profile | |
| Ashley McEvoy | President CEO | Profile | |
| Eric Benjamin | Senior Vice President R&D, New Product Development and Commercialization | Profile | |
| John Kapples | Senior Vice President General Counsel, Secretary | Profile | |
| Wayde McMillan | CFO, Executive Vice President | Profile | |
| Charles Alpuche | Senior Vice President Global Manufacturing and Operations | Profile | |
| Michael Spears | Senior Vice President Quality, Regulatory, and Clinical Affairs | Profile | |
| Flavia Pease | Executive CFO | Profile | |
| Ana Chadwick | Executive CFO | Profile | |
| Mark Field | Senior CTO | Profile | |
| Patricia Dolan | VP Secretary | Profile | |
| Philip Hildale | Senior Care | Profile | |
| Andrew Isaacson | Senior Development | Profile | |
| Laetitia Cousin | Quality Affairs | Profile | |
| Carolyn Sleeth | Senior Manager | Profile | |
| Dan Manea | Senior Officer | Profile | |
| Bret Christensen | Chief Commercial Officer | Profile | |
| June Lazaroff | Senior Relations | Profile | |
| Deborah CPA | Vice Relations | Profile | |
| Lisa Davis | Senior Officer | Profile | |
| Clare Trachtman | Vice Relations | Profile | |
| Patrick Crannell | Senior Manager | Profile | |
| Michael CPA | Advisor | Profile | |
| Prem Singh | Senior Operations | Profile | |
| John JD | Senior Counsel | Profile | |
| Amit Guliani | Interim Engineering | Profile | |
| Angela Wiczek | Senior Communications | Profile | |
| Lauren Budden | Chief VP | Profile | |
| Shacey Petrovic | Chief Commercial Officer | Profile | |
| Trang Ly | Senior Officer | Profile |
About Insulet Management Performance
The success or failure of an entity such as Insulet often depends on how effective the management is. Insulet management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Insulet management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Insulet management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. Insulet Corp operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2300 people.
Please note, the presentation of Insulet's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Insulet's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Insulet's management manipulating its earnings.
Insulet Workforce Analysis
Traditionally, organizations such as Insulet use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Insulet within its industry.Insulet Manpower Efficiency
Return on Insulet Manpower
| Revenue Per Employee | 531.2K | |
| Revenue Per Executive | 69.1M | |
| Net Income Per Employee | 107.3K | |
| Net Income Per Executive | 13.9M | |
| Working Capital Per Employee | 349.5K | |
| Working Capital Per Executive | 45.4M |
Complementary Tools for Insulet Stock analysis
When running Insulet's price analysis, check to measure Insulet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insulet is operating at the current time. Most of Insulet's value examination focuses on studying past and present price action to predict the probability of Insulet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insulet's price. Additionally, you may evaluate how the addition of Insulet to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |